Cepmed promotes the commercialization of high-value services and products from three key technology platforms at the Montreal Heart Institute:

  • The Montreal Heart Institute Biobank
  • The Beaulieu-Saucier Pharmacogenomics Centre
  • The Montreal Health Innovations Coordinating Centre

Together, these platforms enable a wide scope of studies in biomarker discovery, validation, clinical trials that incorporate biomarker testing, and retrospective validation of biomarkers in pre-existing samples. Cepmed facilitates projects that require the coordinated use of all three platforms and benefits from the network and expertise of each.

Montreal Heart Institute Biobank | Cardiovascular Disease Biobank

The Montreal Heart Institute Biobank is one of the largest cardiovascular disease biobanks in the world. It contains high-quality samples with extensive characterization and patient info as well as pre-consented samples for use in retrospective studies. The MHI Biobank coordinates closely with the Montreal Health Innovations Coordinating Centre for acquiring clinical samples and with the Beaulieu-Saucier Pharmacogenomics Centre for proteomic and genomic analysis.

Beaulieu-Saucier Pharmacogenomics Centre | Genomic Analysis and Genetic Research

The Beaulieu-Saucier Pharmacogenomics Centre, established in 2008, is a world class genomics facility. As of 2010, $60mm was invested in building the centre’s infrastructure and platform. The centre has expertise in custom Single Nucleotide Polymorphism (SNP) panel development and Genome Wide Association Studies (GWAS), tools that can be used to identify and validate genomic biomarkers and biomarker panels, and to stratify patients according to drug response.

Montreal Health Innovations Coordinating Centre | Clinical Research

The Montreal Health Innovations Coordinating Centre (MHICC) has completed more than 20 clinical trials (Phase II to IV) and managed more than 750 clinical trial sites worldwide. The MHICC is a leader in the application of a personalized medicine approach to the testing of drugs before market approval, translational medicine and high content clinical trials and participates in both Physician sponsored and corporate sponsored studies. Patient samples collected by MHICC can be stored at the MHI Biobank and analyzed at the Pharmacogenomics Centre at the Montreal Heart Institute.